Our aim is to study the effect of ECT on hippocampal blood flow changes associated with depression.
ID
Source
Brief title
Condition
- Mood disorders and disturbances NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary study parameter will be changes in hippocampal blood flow as a
result of ECT measured in ml/min/100g
Secondary outcome
Differences in hippocampal bloodflow between depressed patients and healthy
controls measured in ml/min/100mg.
Changes in depression score before and after ECT treatment as measured by means
of the Hamilton depression rating scale.
Background summary
Dispite the fact that electroconvulsive therapy (ECT) is one of the most
effective psychiatric therapies, we still have little understanding of how and
why it works. Recent evidence suggests that changes in regional cerebral
bloodflow associated with depression can be reversed through treatment with
ECT. Because most of the supporting evidence comes from animal studies, a
clinical studies are needed to elucidate the pathophysiology in humans. If we
are able to show that ECT can change blood flow associated with depression,
then we are closer to understanding the mechanisms involved in the
pathophysiology of depression and the effect of ECT on these processes. With
time this may lead to better therapies for depression and other psychiatric
diseases.
Study objective
Our aim is to study the effect of ECT on hippocampal blood flow changes
associated with depression.
Study design
Patients meeting the DSM-IV diagnostic criteria for depression will be compared
to healthy control subject on the level of their hippocampal blood flow. Within
the patient group the effect of ECT on hippocampal blood flow will be studied.
The diagnosis will be based on a stuctured interview (SCID). To measure the
level of depression and the effect of ECT the Hamilton Depresion Rating Scale
(HDRS) wil be used. To measure the hippocampal blood flow Arterial Spin
Labelling (ASL) wil be used. ALS is a new MRI technique wherby the protons of
the arterial water in the feeding vasculature of the brain are magnetically
labeled and used as an endogenous tracer.
Study burden and risks
The is no burden outside the investment of time. MRI has been used as a
diagnostic, clinical tool for over 20 years now and there are no known
associated risks. The invested time for the patients amounts to 3.5 hours and
for the healthy controls 2 hours.
Postbus 85500
3508 GA
Nederland
Postbus 85500
3508 GA
Nederland
Listed location countries
Age
Inclusion criteria
Patients who meet DSM-IV criteria for depressive disorder and meet the Dutch Psychiatric Association criteria for electroconvulsive therapy. Healthy control subjects who do not meet any DSM-IV criteria. Age between 18 and 65.
Exclusion criteria
Patients who do not meet DSM-IV criteria for depressive disorder. Healthy controls who meet the criteria for a DSM-IV diagnosis. Subjects who have severe cognitive impairments (e.g. vascular or Alzheimers dementia), severe medical conditions (e.g. coronaire heart disease, COPD, diabetes), non removable metal objects. Subjects who are pregnant or lactating.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL12141.041.06 |